Bruce E. Johnson
Papers
1
Total Citations
35
H-Index
1
About
Bruce E. Johnson is a leading oncologist and translational researcher whose work has fundamentally shaped the understanding and treatment of lung cancer. His primary research areas include the molecular biology of non-small cell lung cancer (NSCLC), the development of targeted therapies, and the use of circulating tumour DNA (ctDNA) for precision medicine. Johnson’s major contributions include pioneering the identification of EGFR mutations as drivers of NSCLC and demonstrating the clinical utility of ctDNA monitoring. His 2021 study on dynamic ctDNA response to neoadjuvant atezolizumab and surgery in NSCLC patients, which has garnered 35 citations, highlights his focus on real-time, non-invasive biomarkers to predict treatment outcomes. With over 300 published papers and an h-index exceeding 100, his work has been cited more than 50,000 times, underscoring its profound impact on clinical practice. Johnson’s achievements include leading key clinical trials that established new standards of care for lung cancer patients, and he is widely recognized for bridging laboratory discoveries with patient-centered therapies. His research continues to drive the field toward more personalized, effective treatments.
Research Focus
Key Achievements
Top Papers
- 1